Patients with non-small-cell lung cancer (NSCLC), the most prevalent subtype of lung cancer, often have a poor 5-year survival rate, mainly due to acquired resistance to therapeutic drugs, such as human epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.